# Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

> **NCT02720536** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 53 (actual)

## Conditions studied

- Chronic Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT02720536
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-16
- **Primary completion:** 2019-07-23
- **Final completion:** 2019-07-23
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720536, "Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02720536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*